No response from IR in relation to my recent email below....

No response from IR in relation to my recent email below. Normally I would receive a response in circa 48 hours. I suppose this one has them stumped?

Thank you for providing the webinar and providing clarity on some points of discussion. I have some further queries below in addition to what was provided in the webinar:

- Relating to current cash on hand position and pending revenues, there doesn't seem to be enough runway to get to the end time frame for the Hologic prototype payments / end of contract. Even with a 100% increase on PCP revenues for products in the next quarter, and flat services revenue matching the most recent quarter revenues (given the reduction in Hologic revenue accounting) it appears that a capital raising will be needed by Q2 2026. Does the company expect to utilise its current lending facilities to continue operations post June 2025 or is the company expecting a substantial increase on product revenues/services revenues to keep operations moving?

- Does the company have capacity to reduce its gross quarterly outgoings to extend the remaining cash on hand? The remaining Hologic revenue for the prototype time frame was extended to be around November 2025 at the earliest with the latest eta being May 2026 (original announcement was 18.01.2024 with original time frame of 18-24 months (November being 18 months plus 4 months delay) etc. Relating to question 1 and the Hologic Phase 3 milestone payment projected after the cash runway at this stage, what is the company doing to ensure capacity to continue operations prior to phase 3 milestone being received?

- Is the company seeing a sufficient testing rate for the Febridx study to meet the time frame for CLIA waiver study (prior to cash runway projection)? From the webinar, 140/800 required patients were tested however this appears slow? Granted the flu season was delayed (now appearing to be in full swing based on available data) does the company have an updated eta on when the CLIA study is likely to achieve its outcome of tested patients based on the current rate of testing?

I appreciate the responses to my queries. There is some concern and discussion around the above with existing shareholders and it appears as though the risk in the company has increased substantially in the last 18 months, even with the news received. This is supported by the recent 52 week low on the share price.